documents: FDA-2020-D-1136-0064

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id agency_id docket_id title document_type subtype posted_date posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2020-D-1136-0064 FDA FDA-2020-D-1136 Resuming Normal Drug and Biologics Manufacturing Operations During the COVID-19 Public Health Emergency Guidance for Industry - September 2020 U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research Center for Other Guidance 2020-09-10T04:00:00Z 2020 9 2021-04-28T04:00:00Z 2023-05-12T03:59:59Z 2023-05-08T19:44:20Z   0 0 0900006484abaf0f

Links from other tables